Recent News

• 07 Dec 2011 - Inviragen Presents Safety and Immune Response Data from a Phase 1 Study of its Two-Dose Dengue Vaccine, DENVax
• 28 Nov 2011 - Inviragen Initiates a Phase 2 Clinical Study of DENVax, a Recombinant, Tetravalent Dengue Vaccine
• 15 Aug 2011 - Inviragen and University of Texas Medical Branch Receive Funding for Development of a Novel Recombinant Chikungunya Virus Vaccine
• 02 Aug 2011 - International Vaccine Institute and Inviragen Announce a Collaboration to Accelerate Development of a Dengue Vaccine
• 15 Jun 2011 - Inviragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore
• 26 Jan 2011 - Inviragen and Duke-NUS Form Collaborative Vaccine Research and Development Program
• 04 Nov 2010 - Novel Recombinant Chikungunya Virus Vaccine Shown to be Safe and Effective in Multiple Animal Models
• 02 Nov 2010 - Inviragen Receives Two Therapeutic Discovery Project Grants for Vaccine Development
• 25 Oct 2010 - Inviragen Initiates DENVax Phase 1 Clinical Testing in Colombia (en español)
• 07 Oct 2010 - Inviragen and PharmaJet Receive $15.5 Million NIAID Contract to Develop a Needle-free Dengue Vaccine
• 18 June 2010 - Inviragen Recognized by “Colorado Companies to Watch” Program
• 19 May 2010 - Inviragen’s Dengue Vaccine to Begin Clinical Testing
• 07 May 2010 - Inviragen Merger Profiled in Inc. Magazine